A clinical study published in 2004 showed that EBV-specific CTLs can be effectively used to treat NPC patients, and proved that EBV-specific CTLs with anticancer properties detected in vitro could increase the LMP2-specific immune response (113). This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.